Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Precigen, Inc.
PGEN
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.6B
$5.64
▲ +7.43%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$1.47 - $6.04
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 226.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
6 reasons
- Proprietary UltraVector platform for complex gene expression programming
- Multiple non-viral and viral delivery technologies (Sleeping Beauty, AdenoVerse, L. lactis)
- UltraCAR-T platform with enhanced immune cell engineering capabilities
- Inducible gene switch systems (RhoSwitch) enabling precise therapeutic control
- Genetically engineered swine technology for regenerative medicine applications
- Extensive patent portfolio and strategic collaborations with established biotech partners
Bear Case
2 risks
- Average volatility.
- Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Strong growth ahead
Expansion of UltraCAR-T clinical programs in oncology indications
Value
Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Hot
+33.3% over 3m
Quality
Excellent
Emerging growth company (500% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying PGEN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 12, 2026
MAY 13, 2026
Reported EPS of -$0.02 vs -$0.03 consensus (+33.3% surprise). Revenue of $23.3M vs $20.8M expected (+11.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+33.3%
Next: May 12, 2026
Revenue trend · last 8Q
—
—
-3%
+26%
+19%
+207%
+284%
+1634%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$717.0K
$953.0K
$1.2M
$1.3M
$856.0K
$2.9M
$4.6M
$23.3M
Margins · last 8Q
Gross
—
Profit
-34.1%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$12.50
▲ +121.6% vs $5.64
Latest: HC Wainwright · $14.00 · May 28, 2026
1 analyst covering